학술논문
The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL
Document Type
Article
Author
Source
In Transplantation and Cellular Therapy May 2023 29(5):311-311
Subject
Language
ISSN
2666-6367